UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

Date of Report: March 13, 2020
(Date of earliest event reported)

Oragenics, Inc.
(Exact name of registrant as specified in its charter)

FL	001-32188	59-3410522
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification Number)

4902 Eisenhower Boulevard, Suite 125 Tampa, FL (Address of principal executive offices)	33634 (Zip Code)

813-286-7900
(Registrant's telephone number, including area code)

(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	OGEN	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [ ]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]

Item 7.01 Regulation FD Disclosure.

Oragenics, Inc. ("Oragenics" or the "Company") will be making virtual investor presentations (the "Investor Presentation") at the 32nd Annual ROTH Conference March 15-17, 2020 and at the 2020 Investor Summit March 25-26, 2020. The Company also expects to use the Investor Presentation from time to time thereafter in connection with presentations to potential investors, industry analysts and others. A copy of the Investor Presentation is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Additionally, the Investor Presentation will be available under the "Presentations" tab in the "News and Media" section of the Company's website, located at www.oragenics.com.

By filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality of any information in this report that is required to be disclosed solely by reason of Regulation FD.

The information contained in the Investor Presentation is summary information that is intended to be considered in the context of the Company's Securities and Exchange Commission ("SEC") filings and other public announcements that the Company may make, by press release or otherwise, from time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports or documents with the SEC, through press releases or through other public disclosure.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.1 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, unless the Company specifically states that the information is to be considered "filed" under the Exchange Act or specifically incorporates it by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Investor Presentation

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 13th day of March 2020.

ORAGENICS, INC.
(Registrant)

BY: */s/ Michael Sullivan*
Michael Sullivan
Chief Financial Officer

Exhibit 99.1


ORAGENICS
Alan F. Joslyn, PhD
President & CEO
813 286 7900 ext 232
ajoslyn@oragenics.com
Oragenics, Inc.
4902 Eisenhower Blvd., Suite 125
Tampa, FL 33634
www.oragenics.com
DEVELOPING NOVEL ANTIBIOTICS AND BIOTHERAPEUTICS THROUGH SYNTHETIC BIOLOGY
Investor Presentation
NYSE American: OGEN

Safe Harbor Statement

Certain statements made in this presentation include forward-looking actions that Oragenics, Inc. ("Oragenics," or the "Company") anticipates based on certain assumptions. These statements are indicated by words such as "expect", "anticipate", "should" and similar words indicating uncertainty in facts, figures and outcomes. Such statements are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. While Oragenics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such statements will prove to be correct. The risks associated with the Company are detailed in the Company's various reports filed by the Company with the Securities and Exchange Commission.


Investment Highlights
1
2
3
Ongoing clinical program in a ~$20MM market cap company with near-term catalysts and sufficient cash through mid-2021
AG013 for Oral Mucositis: Large unmet clinical need - no drug is approved to prevent OM in the broad cancer population;
Addressable Population: >770,000 cancer patients annually in the US
ORAGENICS
Lantibiotics Platform: A novel class of peptide antibacterial compounds, with activity against a variety of MDR infections
3
ORAGENICS

ORAGENICS


AG013: First-in-Class Therapy for
Prevention of Oral Mucositis

Oral Mucositis



- Most common and debilitating complication of cancer chemo and radiation therapy.
- Caused by breakdown of mucosal lining resulting in formation of oral ulcers.
- Inability to eat/drink (WHO grades 3 & 4) resulting in nutritional deficits and potential alterations of cancer treatment regimens.
- **Large Addressable Market**: > 770,000 U.S. newly diagnosed cancer patients receiving conventional chemotherapy and radiation are at increased risk of developing OM*

*Center Disease Control, 2017


Economic and Clinical Impact of Severe OM
Clinical Impact:
3-4x more likely to experience interruption in chemo regimen
2x more likely to receive TPN
2x more likely to have unplanned break in radiation
Mucositis
Economic Impact:
2-8x higher direct hospital costs due to longer stay/delivery of alimentation
9 extra days in the hospital
Nonzee et al Cancer 2008; 113: 1446-52
Vera_Llonch et al Cancer 2006; 106: 329-36
Carlotto et al Pharmacoeconomics 2013; 2013: 753-66
6
ORAGENICS

Economic Impact of Severe OM

TABLE 3
Estimated Costs of Cancer Treatment-related Toxicities Reported by the Northwestern University Costs of Cancer Program[a]

Treatment-related Toxicity (Reference)	Oncology Treatment	Cancer Diagnosis	No. of Patients	Medical Costs, $
Mucositis/pharyngitis (current study)	Radiochemotherapy	Nonsmall cell lung cancer	40	25,060
Neutropenia treated as an inpatient (Albain 2002[b])	Chemotherapy	Lymphoma	11	17,869
Mucositis/pharyngitis (current study)	Radiochemotherapy	Head and neck cancer	99	17,244

Nonzee et al Cancer 2008; 113: 1446-52

AG013: Target Product Profile

- Convenient, flavored oral rinsing solution composed of genetically modified *Lactococcus lactis* (non-pathologic food grade bacterium) engineered to deliver mucosal protectant human Trefoil Factor 1 (hTFF1) to mucosal tissues
  - Trefoil Factors (TFF's) are a class of peptides involved in protecting mucosal tissues against damage and in subsequent repair
- Cost effective (low COGs) delivery system provides daily continuous oropharyngeal coverage with *L. lactis* producing hTFF1 during entire cancer treatment regimen

Intellectual Property:

Intellectual property relating to AG013 extends into 2030s

Additional protections support underlying gene transfer technologies

AG013 in Action

1

AG013 delivers hTTF1 via genetically modified lactococcus

2

The bacteria is freeze-dried into vials

3

Patient mixes powder with a raspberry-flavored solution

4

Patient swishes for 30 seconds after every meal

5



This activity promotes a protein called trefoil factor, which regrows the oral lining


AG013 Superior to Available Treatments
AG013
Kepivance
Sales
TBD
$14,000,000
Patients
>500,000
20,000
(indicated only for bone marrow transplant induction chemo patients)
Method
Oral topical delivery, outpatient
Intravenous, inpatient
$600MM palliative care products provide temporary symptomatic relief
10
* All figures approximate;
ORAGENICS

OM Products Under Development

Company	Oragenics	Galera	Soligenix	Innovation	Monopar
Product Name	AG013: dapatifagene navolactibac	GC 4419: avasopasem manganese	SGX942: dusquetide	Briliciden	Clonidine
Mechanism	Trefoil Factor 1	Superoxide dismutase mimetic	Innate Defense Regulator	Defensin mimetic	α 2 receptor agonist
Route of Administration	Oral rinse system	IV (1 hour infusion)	IV	Oral rinse	Buccal Tablet
Phase of Clinical Development	2/3	3	3	2	2
Market Cap(MM) (3.6.20)	31.9	338.4	61.6	34.9	97.7
Listing/ ticker	NYSE American: OGEN	NASDAQ: GRTX	NASDAQ: SNGX	OTC Markets: IPIX	NASDAQ: MNPR

AG013 Treats a Large Addressable Market With Potential W.W. Cumulative Sales >$2.0Bn for Oral Mucositis

REVENUE-BASED FORECAST ASSUMPTIONS

Potential Addressable Patients Global Market:

6.0 MILLION+

new patients ww/yr

Estimated Peak Share:

20-25%

Estimated Cost:

$90

per day

Global Potential Cumulative Sales: $2.3bn

Treatment Days:

~70

Gross Margin:

90%

AG013: Current Study Design Agreed with FDA

- Double-blind, placebo – controlled evaluation of daily AG013 ($2x10^{11}$ CFU) TID oral suspension for duration of cancer treatment regimen
- 160-180 evaluable patients with head and neck cancer receiving chemoradiation therapy over 7-9 weeks and standard of care for prevention of OM
- ~59 clinical centers in United States and Europe
- **Primary efficacy endpoint:** Duration (in days) of severe OM (WHO grades 3 (unable to eat) & 4 (unable to drink))
- **Sample size consideration:** 160 evaluable patients (80/group) provides 80% power to detect 5-day difference between groups with respect to severe OM
- **OM secondary endpoints:** number of OM free (WHO grades 1 & 2) days, time to onset, use of pain medication, alteration in cancer regimens; emergency room visits for SOM

AG013 Received **FDA Fast Track** Designation

AG013: Near Term News Flow

- 4Q19: Anticipated announcement indicating ongoing clinical study in Head & Neck cancer patients has completed enrollment. **DECEMBER 2, 2019 PRESS RELEASE ANNOUNCING COMPLETION**
- **2.27.20: Last patient completed clinical phase of the study.**
- **Release of topline data: early 2Q20**
- 2/3Q20: Program meetings with FDA and EMA
  - FDA Discussions
    - Breakthrough Therapy
    - End of Phase 2
    - Pediatrics

  European Discussions (EMA & MHRA)
  - Scientific Advice: Orphan Status: Conditional Market Authorization
  - Pediatrics
- 2H20: Licensing discussions with potential partners


AG013: Timeline of Key Events
3Q16
FDA Program Feedback
Protocol design & manufacturing specifications agreement
2Q17
API Manufacture & Packaging Completion
3Q17
Update IND Filing
Activated 11 U.S. clinical sites
3Q17
Treat First Patient in U.S.
2Q18
Interim Safety & Efficacy Review of First 20 Patients
4Q19
Complete Enrollment of ~200 patients
TOPLINE DATA: EARLY 2Q2020
15
ORAGENICS

ORAGENICS


Novel Lantibiotic Platform for
Multidrug Resistant Bacterial Infections

CDC Antibiotic-Resistant Threats, 2017 (cases/yr, US)

Drug-resistant pathogen (blue = gram (+) grey= gram (-))	Infections/year
Clostridium difficile	**500,000**
Carbapenem-Resistant Enterobacteriaceae (CRE)	9,000
Neisseria gonorrhoeae	246,000
MDR Acinetobacter	7,300
Drug-Resistant Campylobacter	310,000
Extended Spectrum ß-lactamase Enterobacteriaceae	26,000
Vancomycin-Resistant Enterococcus (VRE)	**20,000**
MDR *Pseudomonas aeruginosa*	6,700
Drug-Resistant Non-Typhoid Salmonella	100,000
Drug-Resistant Typhoid Salmonella	3,800
Drug-Resistant Shigella	27,000
Methicillin-Resistant *Staphylococcus aureus* (MRSA)	**80,000**
Drug-Resistant *Streptococcus pneumoniae*	**1,200,000**

Center Disease Control; U.S. MDR pathogen update, 2017

C. difficile and *C. difficile* Infection (CDI): Epidemiology

- *C. difficile* is an infection of the colon causing colitis by producing toxins that damage lining of the colon
- 500,000 infections annually resulting in 29,000 deaths
- 83,000 will experience at least one recurrence
- Deaths have increased 400% since 2000
- Healthcare-associated infections occur: 37% hospital onset, 36% nursing home onset, 27% community onset
- *C. difficile* associated diarrhea is associated with a 1-2 week hospital stay
- **Emerging problem**: 8% of CDI associated with onset of concomitant Vancomycin Resistant Enterococci (VRE) infection

Lantibiotics: Novel Platform of Antibiotics to Treat Serious Life-Threatening Infections

- Lantibiotics are novel class of peptide antibacterial compounds naturally produced by variety of Gram-positive bacterial strains to attack competing bacterial strains
- Platform: >700 lantibiotic structures created, potentially generating a pipeline of new compounds
- Prior development limited by manufacturing technical hurdles
- Platform provides potential for development in multidrug resistant infections:
  - Methicillin Resistant *Staphlococcus aureus* (MRSA)
  - Vancomycin Resistant Enterococci (VRE)
  - Virulent *Clostridium difficile*
  - Gram(-) infections

Mutacin 1140: a lantibiotic produced by *Streptococcus mutans*


Oral OG716 Superior at Preventing C. difficile Deaths in Hamster Model
DAY 1
Infection
DAY 2
Clindamycin
DAYS 3-7
Antibiotic Treatment Phase
DAYS 8-22
Recurrence Phase
OG716
Vanco
OG253
Vehicle
Survival (%)
Days
OG716
OG253
Vanco
Vehicle
0
20
40
60
80
100
120
0
5
10
15
20
25
20
ORAGENICS


Lantibiotics: OG716 C. difficile Program Milestones
4Q16
1Q17
3Q19
2Q20 (estimate)
Tech Transfer of Manufacturing Process
Fermentation complete; purification underway
Manufacture of API
Ongoing at 1400L scale; transitioning to GMP manufacture; Enough material generated for rat tox study, lots for monkey tox study ongoing
Toxicology and Microbiology Underway
14-day rat tox study underway and monkey tox study under development
File IND
Timing of filing of the IND is subject to having adequate available capital to complete requisite studies
21
ORAGENICS

ORAGENICS

Capitalization

	Common Stock Equivalents*
Common Stock Outstanding	46,124,803
Series A Convertible Preferred (As Converted)	941,701
Series B Convertible Preferred (As Converted)	1,320,002
Series C Non-Convertible Perpetual Preferred** (113.941 shares outstanding)	-
Warrants (WAEP $1.08)	26,538,593
Reserved for issuance under stock incentive plan	8,009,250
Total	82,934,349

Cash* $18.3M

* Information is as of December 31, 2019.

** As of December 31, 2019, the Non-Voting, Non-Convertible Series C Preferred Shares have a stated value of $33,847 per share and have an accruing dividend of 20% per year. The Series C Preferred Shares resulted from the conversion of approximately $3.3 million in debt obligations previously owed to Intrexon.

The Series A, B, and C Preferred stock have no price based downround protection for the conversion price.

Experienced Management Team

Dr. Alan F. Joslyn
Director, President and Chief Executive Officer

- Assumed CEO position at Oragenics in June 2016
- Held CEO positions at several private biotechnology companies including Sentinella Pharmaceuticals, Edusa Pharmaceuticals and Mt. Cook Pharma
- Formerly sat on the board of Synergy Pharmaceuticals (NASDAQ: SGYP)
- Over 25 years of drug development experience at Glaxo, Johnson & Johnson and Penwest

Mike Sullivan
Chief Financial Officer

- Held senior-level financial positions for both publicly and privately held businesses
- Significant experience in product licensing and IP issues with strong background in both domestic and international retail operations

Dr. Martin Handfield
Senior Vice President, Discovery Research

- Molecular Microbiologist and former Tenured Associate Professor, College of Dentistry at The University of Florida
- Prolific researcher focusing on infectious diseases, host-pathogen interactions and non-invasive diagnostics